ES2268767T3 - Deteccion de cancer de endometrio. - Google Patents

Deteccion de cancer de endometrio. Download PDF

Info

Publication number
ES2268767T3
ES2268767T3 ES98909221T ES98909221T ES2268767T3 ES 2268767 T3 ES2268767 T3 ES 2268767T3 ES 98909221 T ES98909221 T ES 98909221T ES 98909221 T ES98909221 T ES 98909221T ES 2268767 T3 ES2268767 T3 ES 2268767T3
Authority
ES
Spain
Prior art keywords
mmp
uterine
patient
endometrial cancer
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98909221T
Other languages
English (en)
Spanish (es)
Inventor
Alexander Lopata
Lois A. Salamonsen
Michael A. Quinn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diagnotech Pty Ltd
Original Assignee
Diagnotech Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnotech Pty Ltd filed Critical Diagnotech Pty Ltd
Application granted granted Critical
Publication of ES2268767T3 publication Critical patent/ES2268767T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES98909221T 1997-03-20 1998-03-20 Deteccion de cancer de endometrio. Expired - Lifetime ES2268767T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO5736A AUPO573697A0 (en) 1997-03-20 1997-03-20 Diagnosis of endometrial cancer
AUPO5736/97 1997-03-20

Publications (1)

Publication Number Publication Date
ES2268767T3 true ES2268767T3 (es) 2007-03-16

Family

ID=3800039

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98909221T Expired - Lifetime ES2268767T3 (es) 1997-03-20 1998-03-20 Deteccion de cancer de endometrio.

Country Status (14)

Country Link
US (1) US6607894B1 (cg-RX-API-DMAC10.html)
EP (1) EP0979304B1 (cg-RX-API-DMAC10.html)
JP (2) JP4183757B2 (cg-RX-API-DMAC10.html)
KR (1) KR20010006344A (cg-RX-API-DMAC10.html)
CN (1) CN1257550A (cg-RX-API-DMAC10.html)
AT (1) ATE331039T1 (cg-RX-API-DMAC10.html)
AU (1) AUPO573697A0 (cg-RX-API-DMAC10.html)
CA (1) CA2284099C (cg-RX-API-DMAC10.html)
DE (1) DE69835010T2 (cg-RX-API-DMAC10.html)
ES (1) ES2268767T3 (cg-RX-API-DMAC10.html)
MY (1) MY119567A (cg-RX-API-DMAC10.html)
NZ (1) NZ337868A (cg-RX-API-DMAC10.html)
WO (1) WO1998042865A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA982403B (cg-RX-API-DMAC10.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045147A1 (en) * 1998-03-05 1999-09-10 Diadexus Llc A novel method of detecting and monitoring endometrial and uterine cancers
AUPQ219799A0 (en) 1999-08-13 1999-09-02 R. Lurie Pty Ltd Apparatus for obtaining potological samples
US7094754B2 (en) 2001-08-16 2006-08-22 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US7186693B2 (en) 2001-08-16 2007-03-06 Kimberly - Clark Worldwide, Inc. Metalloproteinase inhibitors for wound healing
US6906036B2 (en) 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US7071164B2 (en) 2001-08-16 2006-07-04 Kimberly-Clark Worldwide, Inc. Anti-cancer and wound healing compounds
DE10217677A1 (de) 2002-04-19 2003-11-06 Bayer Ag Verwendung von Aufhellern zur Herstellung von Streichmassen
US7148194B2 (en) 2002-12-30 2006-12-12 Kimberly-Clark Worldwide, Inc. Method to increase fibronectin
US7189700B2 (en) 2003-06-20 2007-03-13 Kimberly-Clark Worldwide, Inc. Anti-chrondrosarcoma compounds
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
EP1782068B1 (en) * 2004-07-23 2010-04-07 Centre de Recherche Public de la Santé Monitoring heart failure
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
WO2006086730A2 (en) * 2005-02-09 2006-08-17 Genentech, Inc. Inhibiting her2 shedding with matrix metalloprotease antagonists
US7504225B2 (en) * 2005-05-12 2009-03-17 Applied Genomics, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
RU2304782C1 (ru) * 2005-12-28 2007-08-20 Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М. Сеченова Способ прогнозирования рецидива эндометриоидной кисты яичника
EP2205642B1 (en) 2007-11-02 2016-01-27 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
DK2419736T3 (da) * 2009-04-16 2014-04-22 Momenta Pharmaceuticals Inc Fremgangsmåder til vurdering af aktivitet af en polysaccharidsammensætning
CN105132529A (zh) * 2009-07-24 2015-12-09 吉第克生物技术有限公司 子宫内膜癌的标记物
BR112012026542A2 (pt) 2010-04-16 2016-07-12 Momenta Pharmaceuticals Inc abordagem seletiva de tecido
RU2430371C1 (ru) * 2010-04-26 2011-09-27 Учреждение Российской академии наук Институт ядерной физики им. Г.И. Будкера Сибирского отделения РАН (ИЯФ СО РАН) Способ дифференциальной диагностики и прогноза миомы и рака эндометрия
AU2011268470B2 (en) 2010-06-17 2017-02-02 Momenta Pharmaceuticals, Inc. Methods and compositions for promoting hair growth
CA2838053A1 (en) * 2011-06-03 2012-12-06 University Of South Alabama Methods and compositions for detecting endometrial or ovarian cancer
CN107389936A (zh) * 2011-09-22 2017-11-24 斯隆-凯特林纪念癌症中心 检测卵巢癌
HRP20181726T1 (hr) * 2012-01-31 2018-12-28 SPEISER, Paul Neinvazivno dijagnosticiranje raka
US10016449B2 (en) 2013-05-28 2018-07-10 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
AU2015283811A1 (en) * 2014-07-02 2017-02-09 Bionomics Limited Predictive biomarkers
CA2975737A1 (en) * 2015-02-06 2016-08-11 Quest Diagnostics Investments Llc Compositions and methods for determining endometrial cancer prognosis
PT3452829T (pt) * 2016-05-04 2024-03-22 Fundacio Hospital Univ Vall Dhebron Institut De Recerca Perm como marcador de cancro endometrial
IN202021002695A (cg-RX-API-DMAC10.html) 2020-01-21 2021-07-23
CN112961921B (zh) * 2021-03-26 2022-07-01 中国医学科学院北京协和医院 一种用于判断早期子宫内膜癌预后的制剂及复发风险模型

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280106A (en) * 1988-05-20 1994-01-18 Liotta Lance A Matrix metalloproteinase peptides: role in diagnosis and therapy
US5324634A (en) * 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
WO1994005807A1 (en) * 1992-08-28 1994-03-17 Dickson Robert B Matrix-degrading metalloproteinase
JPH09503901A (ja) * 1992-11-16 1997-04-22 キャンサー リサーチ ファンド オブ コントラ コスタ 広範な新生物特異性を有するペプチドおよびアンチセンスペプチド

Also Published As

Publication number Publication date
MY119567A (en) 2005-06-30
WO1998042865A1 (en) 1998-10-01
EP0979304A4 (en) 2003-06-11
AUPO573697A0 (en) 1997-04-10
DE69835010D1 (de) 2006-08-03
EP0979304B1 (en) 2006-06-21
JP2002501613A (ja) 2002-01-15
JP4183757B2 (ja) 2008-11-19
ATE331039T1 (de) 2006-07-15
DE69835010T2 (de) 2007-06-06
US6607894B1 (en) 2003-08-19
NZ337868A (en) 2002-05-31
CN1257550A (zh) 2000-06-21
CA2284099A1 (en) 1998-10-01
KR20010006344A (ko) 2001-01-26
EP0979304A1 (en) 2000-02-16
JP2007202556A (ja) 2007-08-16
ZA982403B (en) 1998-10-21
CA2284099C (en) 2010-04-27

Similar Documents

Publication Publication Date Title
US6607894B1 (en) Matrix metalloproteinase levels as indicators of endometrial cancer
Bianco Jr et al. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade.
Eissa et al. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine
ES2481672T3 (es) Marcadores para la detección del cáncer gástrico
Singh et al. Matrix metalloproteinases and their inhibitors: correlation with invasion and metastasis in oral cancer
Bonk et al. Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues
ES2399443T3 (es) Método in vitro para diagnosticar y monitorizar carcinoma de células renales (RCC) usando MMP-7 como biomarcador humora para el RCC
CN112601961B (zh) 通过尿液生物标志物的方式体外诊断前列腺癌的方法
Di Carlo et al. Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors
JP5155309B2 (ja) 患者の循環液中のMMP−7の測定を利用した転移した膀胱ガンを診断およびモニターするためのinvitro方法
Warwas et al. Cathepsin B-like activity as a serum tumour marker in ovarian carcinoma
WO2020262429A1 (ja) がんのバイオマーカーおよびがんの発症を判定する方法
Yang et al. A Significant Elevation of Plasma Level of Matrix Metalloproteinase—9 in Patients With High-Grade Intraepithelial Neoplasia and Early Squamous Cell Carcinoma of the Uterine Cervix
RU2613302C1 (ru) Способ определения продолжительности безрецидивного периода при серозном раке яичников
ES2264696T3 (es) Test inmunologico y kit de diagnostico de un adenocarcinoma de prostata.
RU2690379C1 (ru) Способ прогнозирования темпов роста лейомиомы матки у женщин репродуктивного возраста
AU728286B2 (en) Detection of endometrial cancer
CN116087522A (zh) 胰腺癌肿瘤分子标志物tnk2及检测试剂盒及其应用
Özden et al. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA
Bazzett et al. Urinary matrix metalloproteinases as a potential screening test for gynecologic malignancies
MXPA99008616A (en) Detection of endometrial cancer
Bhattacharyya et al. α1-Antitrypsin: A possible tool for diagnosis of cervical cancer
Attallah et al. Combining nuclear matrix protein-52, collagen III, and matrix metalloproteinase-1 for more effective breast cancer early detection
RU2722654C1 (ru) Способ прогнозирования перитонеального распространения рака яичников
UMANA et al. COMPARISON OF PROSTATE HEALTH INDEX VS PROSTATE-SPECIFIC ANTIGEN IN PROSTATE CANCER DETECTION AMONG MEN WITH PROSTATE-SPECIFIC ANTIGEN 4–10 NG/ML IN JOS